Eli Lilly expanded its immunology pipeline by acquiring Merida Biosciences for up to $2.875 billion, while Takeda and Protagonist gained FDA approval for their novel polycythemia vera drug Mimrylo. Meanwhile, Novartis and Bristol Myers paused autoimmune CAR-T trials over safety concerns, and McKesson faced a $55 million ransom demand following a major cloud data breach. Solstice shares jumped 12.8 percent after canceling a $14.5 billion merger to execute a $500 million buyback instead.
01Risk signal
Novartis and Bristol Myers Pause Autoimmune CAR-T Trials Due to Safety Concerns
Linking accelerated manufacturing to systemic inflammation directly undermines the economic thesis that faster production cycles can make CAR-T therapies viable for mass autoimmune markets.
Novartis and Bristol Myers Squibb have halted multiple testing cell therapies in autoimmune diseases following severe inflammatory side effects. Novartis paused development of its personalized CAR-T treatment, rap-cel, on Aug. 24 after detecting three cases of immune effector cell-associated hemophagocytic syndrome. The hold affects studies evaluating rap-cel across multiple indications including lupus, myasthenia gravis, and multiple sclerosis. Bristol Myers voluntarily paused enrollment in trials for its own CAR-T therapy, zola-cel, after observing transient inflammatory events during routine safety surveillance. Both therapies rely on rapid manufacturing platforms designed to speed up production compared to older treatments. William Blair analyst Sami Corwin noted that this accelerated manufacturing process could be driving increased cell expansion and the resulting toxicities. While both companies have paused their autoimmune work, their cancer programs involving the respective therapies remain active.
Asian Healthcare Deals Surge on Brain Tech and Surgical Robotics Investments
Deploying clinical artificial intelligence into hospital workflows shifts healthcare venture returns from long-dated drug discovery timelines toward immediate operational monetization in operating rooms.
scmp.com reports that private investors in Asia are increasing their allocations to brain-computer interfaces and surgical robotics as regional healthcare deal activity accelerates. Bain and Company data shows the number of healthcare funds active in Asia-Pacific deals nearly doubled to 129 in the first half of the year, compared to 66 in the same period a year earlier. Globally, the healthcare private equity sector recorded 184 buyout deals during the same timeframe, while total disclosed deal value declined by 18 percent year on year to US$51 billion. William Chow, deputy group CEO of Raffles Family Office, notes that structural demand driven by an aging Asian population is directing toward advanced surgical technologies. Raffles Family Office manages approximately US$2 billion in . Meanwhile, Ryoden Medical Holdings founder and CEO Charles Hu highlights moving past drug discovery into clinical hospital workflows for real-time surgical feedback.
Asia-Pacific Healthcare PE Funds (count)
The number of active healthcare private equity funds nearly doubled in a year
Eli Lilly to Acquire Merida Biosciences for $2.88 Billion
Selective antibody degradation shifts immunology M&A from broad immunosuppression toward targeted clearance platforms, forcing legacy symptom-blocking therapies to defend their market share against curative mechanisms.
Eli Lilly is acquiring Merida Biosciences for up to $2.875 billion in cash, adding an experimental biotechnology platform designed to eliminate malfunctioning antibodies that drive autoimmune disorders. Merida's lead drug candidate, MER511, is currently in a Phase 1 for Graves disease and thyroid eye disease, conditions that lack treatments directly targeting their underlying autoantibodies. Rather than broadly suppressing the immune system like traditional therapies, Merida's platform uses engineered to selectively bind and degrade disease-causing agents while preserving normal immune function. The transaction marks Lilly's thirteenth company of 2026, fueled by cash flows from its dominant obesity and diabetes treatments. The purchase price includes an undisclosed upfront payment alongside contingent milestone payments. The deal requires regulatory approval and is expected to close in the fourth quarter of 2026.
FDA Approves Takeda and Protagonist Drug for Rare Blood Disorder
Mimrylo's approval proves that synthetic hepcidin mimetics can disrupt chronic phlebotomy regimes, creating a new therapeutic class that replaces invasive procedure-based care with recurring specialty biologic revenue.
The US Food and Drug Administration approved Mimrylo to treat adults with polycythemia vera. Developed by Takeda and Protagonist Therapeutics, the drug is the first approved treatment for the rare blood disorder that mimics hepcidin to regulate iron and limit red blood cell overproduction. Patients with the condition often require frequent phlebotomies to maintain hematocrit levels below 45 percent and reduce cardiovascular risks like blood clots and strokes. In the VERIFY study of 293 adults requiring frequent phlebotomies despite standard care, 76.9 percent of patients receiving Mimrylo needed no phlebotomies between weeks 20 and 32 compared to 32.9 percent on placebo. The drug was administered subcutaneously once weekly starting at 19 mg and received priority review.
VERIFY Trial Phlebotomy-Free Rate (%)
Mimrylo patients avoided phlebotomies at more than twice the placebo rate.
Solstice Shares Surge After $14.5 Billion Merger Ends in Favor of $500 Million Buyback
Trading execution risk for capital return rewards shareholders when manufacturing turnaround costs already constrain margin expansion.
Solstice shares jumped 12.8 percent to close at $63.53 on Friday after the company scrapped its planned $14.5 billion with Element Solutions. Management replaced the deal with a $500 million share repurchase program, removing the integration risks of a transaction that would have nearly doubled the firm's size. Neither company will pay a termination fee. The accounts for roughly 5 percent of the company's value. Second-quarter net sales rose 11 percent to $1.148 billion, though adjusted grew just 2 percent to $290 million as plant turnarounds weighed on margins. Management reaffirmed its full-year sales outlook of $4.125 billion to $4.185 billion and adjusted EBITDA between $1.035 billion and $1.055 billion.
SEC and FDA Sign MOU to Enhance Market Cooperation
Cross-agency information sharing connects FDA trial data directly to SEC disclosure enforcement, exposing life sciences management to immediate fraud liability for misrepresenting clinical progress.
The Securities and Exchange Commission and the Food and Drug Administration entered into a memorandum of understanding on August 31, 2026, to coordinate regulatory and enforcement efforts across public markets. The agreement establishes formal information-sharing protocols between the two agencies to oversee life sciences companies and enforce federal securities disclosures. SEC Chairman Paul S. Atkins and Acting Commissioner Kyle Diamantras J.D. signed the framework to protect public health and market integrity. The memorandum remains in effect for a period of three years, with future extensions requiring mutual written consent from both regulators.
McKesson Reportedly Suffers Data Breach Affecting Millions of Patient Records
Breaching cloud databases at a primary medical distributor converts routine inventory data into operational extortion, directly tying healthcare supply chain continuity to cybersecurity liabilities.
TechCrunch reports that hackers breached McKesson's cloud-hosted accounts last week, exfiltrating sensitive patient records from its and medical-surgical units. The ShinyHunters hacking group claimed responsibility, stating they accessed the network via phishing and social engineering tricks to steal millions of rows of personal and health data from Snowflake and Salesforce environments. The hackers demanded a $55 million ransom to withhold the stolen files, while McKesson confirmed the incident and warned of intermittent service degradation. The attack forces healthcare providers to review cloud security protocols as extortion crews increasingly target medical distributors.
Targeted M&A and novel drug approvals continue to drive sector value despite clinical pauses and severe cyber vulnerabilities in healthcare infrastructure. The unresolved question is whether heightened SEC and FDA oversight will slow future life sciences dealmaking and clinical pipelines.
This, every morning.
SuMarket writes Healthcare and Pharmaceutical Sector every morning, along with every other section of the market and the companies and topics you follow. Free to read.